The Use Of Cell Therapy Isolators To Reduce Batch Contamination

Advancements in 4.0 pharma are driving the need for facility design solutions to deliver cost savings.

Cell and gene therapies are currently produced in facilities that require significant upfront investment and high per patient cost. The future of facility design is leaning on pillars including automation and innovation to reshape the way we use fixed assets and the production process as a whole.

Integration of closed processes such as isolators into the largely human workflow is an increasingly effective method to adopt production efficiency that improves patient safety and reduces contamination along with overall costs.

Modern offerings such as modular concepts provide an opportunity to shift from larger, fixed assets or open environments to networks of smaller processing systems.